Meeting
2012 Genitourinary Cancers Symposium
Skeletal events unrelated to bone metastasis in men with castration-refractory prostate cancer.
Authors
Kazumi Kamoi
Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
Kazumi Kamoi , Koji Okihara , Natsuki Takaha , Tsuyoshi Iwata , Akihiro Kawauchi , Tsuneharu Miki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 85)
DOI
10.1200/jco.2012.30.5_suppl.85
Abstract #
85
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Use of serum markers in prediction of survival in the trapeze factorial trial evaluating docetaxel with zoledronic acid, strontium-89, or both in castrate-refractory prostate cancer (CRPC) metastatic to bone.
First Author: Vivek K Wadhwa
Poster
2013 Genitourinary Cancers Symposium
Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).
First Author: Matthew Raymond Smith
Poster
2012 Genitourinary Cancers Symposium
Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
First Author: Michael E. Rader
Poster
2012 Genitourinary Cancers Symposium
Use of radiographic progression to predict overall survival in men with castration-refractory prostate cancer.
First Author: Kazumi Kamoi